Aderhold Neuroleptika minimieren 6.0 - BGSP

2527 Coryell W, Miller DD, Perry PJ.(1998):Haloperidol plasma levels and dose optimization. Am J Psychiatry 155(1):48-53.28Mosher, L. R. & Bola, J. R. (2004). Soteria-California and its American successors: Therapeutic ingredients. EthicalHuman Psychiatry and Psychology, 6(1), 147–163.Mosher,L. R., Hendrix, F., with Fort D.C: Soteria – through madness to deliverance 2004To Order: Xlibris Corporation, www.Xlibris.com, Orders@Xlibris.com29 Deutch AY.(1990): The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of centraldopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl. 1992;36:61-89.30 Lader M and the NIDS working group (1993): Neuroleptic-induced deficit syndrome (NIDS). J Clin Psychiatry 54:494-500Schooler NR.(1994): Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. ActaPsychiatr Scand Suppl. 380:21-6.31 Heinz A, Knable MB, Coppola R, Gorey JG, Jones DW, Lee KS, Weinberger DR.(1998): Psychomotor slowing, negativesymptoms and dopamine receptor availability—an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenicpatients. Schizophr. Res. 31(1):19-26.de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J.(2000): Subjective experience and striatal dopamine D(2)receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 157(6):1019-20.32 Leucht S, Pitschel-Walz G, Engel RR, Kissling W.(2002): Amisulpride, an unusual "atypical" antipsychotic: a metaanalysisof randomizedcontrolled trials. Am J Psychiatry.159(2):180-90.33 Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S.(2006): The treatment of negative symptoms and deficitstates of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlledclinical trial. Acta Psychiatr Scand. 114(5):319-27.34 Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S.(2006):The treatment of negative symptoms and deficitstates of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlledclinical trial.Acta Psychiatr Scand. 114(5):319-27.35 Tollefson GD, Sanger TM.(1997): Negative symptoms: a path analytic approach to a double-blind, placebo- andhaloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 154(4):466-74.36 Murphy BP, Chung YC, Park TW, McGorry PD.(2006): Pharmacological treatment of primary negative symptoms inschizophrenia: a systematic review. Schizophr Res.88(1-3):5-25. Epub 2006 Aug 23.37 Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffectivedisorder. J Clin Psychiatry. 63(9):763-71.Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.(2003): Aripiprazole, anantipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia andschizoaffective disorder. Arch Gen Psychiatry. 60(7):681-90.38 Leucht S, Pitschel-Walz G, Engel RR, Kissling W.(2002): Amisulpride, an unusual "atypical" antipsychotic: a metaanalysisof randomizedcontrolled trials. Am J Psychiatry.159(2):180-90.39 Leucht S, Pitschel-Walz G, Engel RR, Kissling W.(2002): Amisulpride, an unusual "atypical" antipsychotic: a metaanalysisof randomizedcontrolled trials. Am J Psychiatry.159(2):180-90.Buchanan RW.(2007): Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 33(4):1013-22.Speller JC, Barnes TR, Curson DA, Pantelis C, Alberts JL.(2007): One-year, low-dose neuroleptic study of in-patients withchronic schizophrenia characterised by persistent negative symptoms. Amisulpride v.haloperidol.Br J Psychiatry. 171:564-8.